会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 43. 发明申请
    • PROTEIN TYROSINE PHOSPHATASE MUTATIONS IN CANCERS
    • 蛋白质酪氨酸磷酸酶突变体
    • WO2005113824A3
    • 2006-06-29
    • PCT/US2005017105
    • 2005-05-16
    • WANG ZHENGHEVELCULESCU VICTORKINZLER KENNETH WVOGELSTEIN BERT
    • WANG ZHENGHEVELCULESCU VICTORKINZLER KENNETH WVOGELSTEIN BERT
    • C12Q1/68
    • C12Q1/6886C12N9/16C12Q2600/112C12Q2600/136C12Q2600/156C12Q2600/158C12Y301/03048G01N33/5011G01N2333/916
    • Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis. A mutational analysis of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14) affecting 26 % of colorectal cancers and a smaller fraction of lung, breast and gastric cancers. Fifteen mutations were nonsense, frameshift or splice site alterations predicted to result in truncated proteins lacking phosphatase activity. Five missense mutations in the most commonly altered PTP (PTPRP) were biochemically examined and found to reduce phosphatase activity. Expression of wild-type but not a mutant PTPRT in human cancer cells inhibited cell growth. These observations suggest that the tyrosine phosphatase genes are tumor suppressor genes, regulating cellular pathways that may be amenable to therapeutic intervention.
    • 由蛋白酪氨酸磷酸酶(PTP)和激酶(PTK)调节的酪氨酸磷酸化在肿瘤发生的信号通路中是重要的。 人类癌症中酪氨酸磷酸酶基因超家族的突变分析鉴定了影响26%结肠直肠癌和较小部分肺癌,乳腺癌和胃癌的6种PTPs(PTPRF,PTPRG,PTPRT,PTPN3,PTPN13,PTPN14)中的83个体细胞突变。 十五个突变是无义,移位或剪接位点改变,预计会导致截短的蛋白质缺乏磷酸酶活性。 在生物化学检查中发现最常改变的PTP(PTPRP)中的五个错义突变被发现可以降低磷酸酶活性。 野生型但不是突变PTPRT在人类癌细胞中的表达抑制细胞生长。 这些观察表明,酪氨酸磷酸酶基因是肿瘤抑制基因,调节可能适合于治疗性干预的细胞途径。
    • 45. 发明申请
    • SAFE SEQUENCING SYSTEM
    • 安全排序系统
    • WO2012142213A3
    • 2013-01-24
    • PCT/US2012033207
    • 2012-04-12
    • UNIV JOHNS HOPKINSVOGELSTEIN BERTKINZLER KENNETH WPAPADOPOULOS NICKOLASKINDE ISAAC
    • VOGELSTEIN BERTKINZLER KENNETH WPAPADOPOULOS NICKOLASKINDE ISAAC
    • C12Q1/68C12N15/11
    • C12Q1/6874C12Q1/6806C12Q1/6869C12Q1/6876C12Q2563/179C12Q2600/158C12Q2535/122C12Q2565/514
    • The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called "Safe-SeqS" for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant ("super-mutants") if =95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.
    • 存在于DNA模板的一小部分中的突变的鉴定对于在几个生物医学研究领域的进展是必不可少的。 尽管大规模并行测序仪器原则上非常适合于此任务,但是这些仪器中的错误率通常太高,无法确定罕见的变体。 我们在这里描述了一种可以显着增加大规模并行测序仪器对此目的的灵敏度的方法。 这种方法的一个例子是(Safe-Sequencing System),称为“Safe-SeqS”,包括(i)将唯一标识符(UID)分配给每个模板分子; (ii)每个唯一标记的模板分子的扩增以产生UID家族; 和(iii)扩增产物的冗余测序。 具有相同UID的PCR片段是真正的突变体(“超突变体”),如果其中95%含有相同的突变。 我们说明了这种方法用于确定聚合酶的保真度,体外合成的寡核苷酸的准确性以及正常细胞的核和线粒体基因组中突变的流行率的效用。